Aitia, Pancreatic Cancer Action Network Strike Drug Collaboration Deal
Joint venture aims to drive new discoveries and improve patient outcomes.
In a company press release, Aitia announced a collaboration with the Pancreatic Cancer Action Network (PanCAN) focused on accelerating drug discovery and development. Through applying PanCAN's Spark health data platform, Atita intends to integrate de-identified human multi-omic data to create gemini digital twins, that will serve a wide range of applications, including the discovery of novel targets and biomarkers, simulation of drug candidates, identification of ideal patient subpopulations for clinical trials, and the determination of optimal drug combinations.
"Unraveling the complex genetic and molecular circuitry of Pancreatic Cancer is critical to the discovery of the next generation of drugs that can significantly increase the survival rate of patients," said Colin Hill, CEO, co-founder, Aitia. "We believe our Gemini Digital Twins, coupled with PanCAN's robust de-identified human multi-omic data, stand to increase efficacy in early research, ultimately leading to the discovery and development of breakthrough drugs. Collaborating with PanCAN is a pivotal milestone in our mission, as we envision reshaping the panorama of pancreatic cancer treatment by harnessing the potential of multi-omic patient data, Causal AI and Digital Twins".
Reference: Aitia and Pancreatic Cancer Action Network Partner to Transform De-Identified Multi-Omic Patient Data into Digital Twins to Drive New Discoveries and Improve Patient Outcomes. PR Newswire. September 27, 2023. Accessed September 28, 2023. https://www.prnewswire.com/news-releases/aitia-and-pancreatic-cancer-action-network-partner-to-transform-de-identified-multi-omic-patient-data-into-digital-twins-to-drive-new-discoveries-and-improve-patient-outcomes-301940556.html
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
